Via Scoop.it – Virology News
Inovio Pharmaceuticals (AMEX:INO) received a second grant by the U.S. Defence Department to fund bioterrorism synthetic vaccines program, the company said Monday.
The grant allows Inovio to advance development of a low-cost, non-invasive surface electroporation delivery device and test its utility with its novel synthetic DNA-based vaccines against viruses with a bioterrorism potential, including hanta, puumala,
arenavirus and pandemic influenza.
Good may come of the bioterror hype yet!
Leave a Reply